Passion for Innovation. Compassion for Patients.™
Daiichi Sankyo Europe GmbH
Dear User,
This website provides you with information only for healthcare professionals. According to the drug
promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have
full access to our website. To visit our page please login.
European News
Daiichi Sankyo Receives Negative CHMP Opinion for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Daiichi Sankyo
2019-10-18 17:00:56
Daiichi Sankyo Receives Negative CHMP Opinion for FLT3 Inhibitor Quizartinib for Treatment of Patients with
[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with HER2 Positive Metastatic Breast Cancer
Daiichi Sankyo
2019-10-17 14:45:37
[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with HER2
European results from Global ETNA-AF registry show low bleeding and low cardiovascular event rates in elderly NVAF patients on LIXIANA®▼ (edoxaban)
Daiichi Sankyo
2019-10-17 09:32:02
European results from Global ETNA-AF registry show low bleeding and low cardiovascular event rates in elderly
The Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid Completes Patient Enrolment
Daiichi Sankyo
2019-10-14 09:32:47
The Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid Completes Patient Enrolment
Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo’s DS-1062 in Patients with Advanced NSCLC at 2019 World Conference on Lung Cancer
Daiichi Sankyo
2019-09-10 11:16:59
Updated Clinical Results and New Biomarker Analyses Presented for Daiichi Sankyo’s DS-1062 in Patients with
Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer
Daiichi Sankyo
2019-09-10 10:57:52
Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World
Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2 Positive Metastatic Breast Cancer
Daiichi Sankyo
2019-09-09 12:53:03
Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2
Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA® (edoxaban) in Patients with Atrial Fibrillation
Daiichi Sankyo
2019-09-04 11:00:59
Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA® (edoxaban) in Patients with
ETNA-AF Registry Data Provide Real-world Evidence of the Efficacy and Safety Profile of LIXIANA® (edoxaban) in Elderly NVAF Patients
Daiichi Sankyo
2019-09-02 14:42:31
ETNA-AF Registry Data Provide Real-world Evidence of the Efficacy and Safety Profile of LIXIANA® (edoxaban) in
Positive Results Highlight Potential of Bempedoic Acid / Ezetimibe Combination for Hypercholesterolaemia with Type 2 Diabetes
Daiichi Sankyo
2019-08-29 15:14:00
Positive Results Highlight Potential of Bempedoic Acid / Ezetimibe Combination for Hypercholesterolaemia with
More Stories
